Outcome of Board Meeting held on Thursday, 13th November, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved unaudited financial results for Q2 and H1 FY26 (ended September 30, 2025). Revenue from operations fell to ₹1,838.20 lakh in Q2 FY26 from ₹1,977.43 lakh in Q2 FY25 (~7% decline), while H1 revenue dipped marginally to ₹3,613.70 lakh from ₹3,664.21 lakh. Net profit dropped more sharply to ₹78.60 lakh in Q2 (vs ₹120.12 lakh) and to ₹177.94 lakh in H1 (vs ₹215.63 lakh), with EPS at ₹1.38 for Q2 (vs ₹2.40). The board also approved a revision in MD Tushar Patel's remuneration effective December 1, 2025, and his re-appointment as Managing Director for three years from August 1, 2026, both subject to shareholder approval via postal ballot. The auditor's review report is clean with no qualifications. The company raised ₹358.80 lakh via a preferential allotment of 6.90 lakh equity shares to promoters at ₹52/share in May 2025.
Weak Q2 numbers with sharper profit decline than revenue dip suggest margin pressure, though recent equity infusion and improved operating cashflow (₹280 lakh vs ₹94 lakh) strengthen the balance sheet. Shareholders will vote on key management-related proposals via postal ballot.